TrialClinical cardiology2017

A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9.

Amos Baruch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.